An outspoken critic of the United States Food and Drug Administration (FDA), Dr. Vinay Prasad has resigned from the organization amid drug-related controversy. Prasad stepped down following a series of controversial decisions related to a treatment for boys with Duchenne muscular dystrophy, according to Stat News.
“Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,” a spokesperson for the U.S. Department of Health and Human Services told CNN on Tuesday.
CNN reports that according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, Prasad’s departure came amid fresh pressure from the White House for him to resign, and followed days of criticism from Laura Loomer, a right-wing activist with extraordinary access to President Donald Trump.
READ: AcmeSolv wins $43 billion contract by the Defense Health Agency (July 28, 2025)
Prasad had been defended by FDA Commissioner Dr. Marty Makary just days ago; in an interview with Politico, Makary said Prasad is an “impeccable scientist … one of the greatest scientific minds of our generation.”
Dr. Vinay Prasad is a prominent hematologist-oncologist and health policy researcher known for his critical analysis of medical research, FDA drug approvals, and healthcare practices. He emphasizes the importance of rigorous evidence and transparency in the approval and use of new treatments, often highlighting cases where FDA decisions have been influenced by limited or low-quality data.
Prasad advocates for stronger standards in clinical trials and challenges the overuse of costly or unproven therapies in medicine. Through his writings, podcasts, and social media presence, he has become a respected voice in promoting evidence-based medicine and improving regulatory processes. While he is not affiliated with the FDA as an official member, his critiques and insights often target FDA policies, aiming to encourage reforms that better protect patients and improve healthcare outcomes. His work has sparked important conversations about balancing innovation with patient safety in modern medicine.
READ: Indian American couple establish endowed chair at Texas University (July 24, 2025)
Dr. Prasad’s resignation from the FDA marks a significant moment in ongoing debates about the agency’s role, transparency, and scientific rigor. Known for his outspoken critiques of FDA practices, Prasad consistently emphasized the need for stronger evidence and higher standards in drug approvals to protect patient safety. His departure, reportedly influenced by political pressures and public criticism, highlights the complex intersection of science, policy, and politics within regulatory bodies.
Despite his brief tenure, Prasad’s influence extends beyond the FDA through his advocacy for evidence-based medicine and calls for reform in healthcare regulation. The support he received from FDA Commissioner Makary underscores his respected scientific standing, even amid controversy.